Feed OTSKF
OT

Otsuka Holdings Co., Ltd. OTSKF OTC · Healthcare · Japan

$73.16 +0.00% +$0.00

Summary

77 / 100 · Bulios Score

What speaks for it

  • Earnings per share grew by 41% a year over the last 3 years.
  • Out of every 100 JPY of revenue, 14 JPY is left as net profit.
  • It holds more cash than debt: ¥472.5B against ¥191.5B.
  • The share price is below the Bulios Fair Price.

What to watch

  • Earnings per share swing sharply from year to year.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Undervalued Price today $73.16

By our assumptions the business is worth more than its shares cost today.

P/E today 15.8 7.7% lower
5-year average P/E 17.2
P/E today 15.8
Drug Manufacturers - General industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 15.8 JPY for 1 JPY of yearly profit. Over the last five years it was 17.2 JPY on average.

Valuation in detail

Is it growing?

Yes, fast

Revenue (JPY)

Diluted EPS (JPY)

  • Analyst estimate

Revenue grew by 12% a year over 5 years. Over the last 3 years it grew by 12% a year. For the next fiscal year analysts expect revenue to grow by 10%. Earnings per share grew by 41% a year over the last 3 years.

Growth in detail

Does it make money?

Very well

Where 100 JPY of revenue goes

Net profit, industry median (Drug Manufacturers - General) 14 JPY

Out of every 100 JPY of revenue, 14 JPY is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

It could repay all its debt from a single year of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

Small, safe
Yield
1.24%
Paid out of profit
20%
Raised in a row
2 years

You receive $0.90 per share a year. The company covers the payout with ease.

Dividends in detail

What do analysts expect?

No coverage

No analyst covers this stock.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy